Silence Therapeutics plc

NasdaqGM:SLN Lagerbericht

Marktkapitalisierung: US$827.4m

Silence Therapeutics Management

Management Kriterienprüfungen 2/4

Silence Therapeutics' CEO is Craig Tooman, appointed in Feb 2022, has a tenure of 2.75 years. total yearly compensation is £7.30M, comprised of 6.5% salary and 93.5% bonuses, including company stock and options. directly owns 0.024% of the company’s shares, worth $197.33K. The average tenure of the management team and the board of directors is 2.1 years and 4.8 years respectively.

Wichtige Informationen

Craig Tooman

Geschäftsführender

UK£7.3m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts6.5%
Amtszeit als Geschäftsführer2.8yrs
Eigentum des Geschäftsführers0.02%
Durchschnittliche Amtszeit des Managements2.1yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder4.8yrs

Jüngste Management Updates

Recent updates

Some Shareholders Feeling Restless Over Silence Therapeutics plc's (NASDAQ:SLN) P/S Ratio

Oct 04
Some Shareholders Feeling Restless Over Silence Therapeutics plc's (NASDAQ:SLN) P/S Ratio

Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 18
Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Silence Therapeutics plc's (NASDAQ:SLN) Shareholders Might Be Looking For Exit

Jun 17
Silence Therapeutics plc's (NASDAQ:SLN) Shareholders Might Be Looking For Exit

Here's Why We're Not Too Worried About Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation

May 21
Here's Why We're Not Too Worried About Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation

Need To Know: Analysts Are Much More Bullish On Silence Therapeutics plc (NASDAQ:SLN) Revenues

Feb 07
Need To Know: Analysts Are Much More Bullish On Silence Therapeutics plc (NASDAQ:SLN) Revenues

Subdued Growth No Barrier To Silence Therapeutics plc (NASDAQ:SLN) With Shares Advancing 65%

Nov 27
Subdued Growth No Barrier To Silence Therapeutics plc (NASDAQ:SLN) With Shares Advancing 65%

Silence Therapeutics wins FDA’s fast track status for blood cancer therapy

Sep 08

Silence Therapeutics prices 5.95M ADSs at $9.50/share

Aug 12

New finance chief for Silence Therapeutics

Jan 06

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Craig Tooman im Vergleich zu den Einnahmen von Silence Therapeutics verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Jun 30 2024n/an/a

-UK£40m

Mar 31 2024n/an/a

-UK£35m

Dec 31 2023UK£7mUK£473k

-UK£43m

Sep 30 2023n/an/a

-UK£43m

Jun 30 2023n/an/a

-UK£41m

Mar 31 2023n/an/a

-UK£43m

Dec 31 2022UK£6mUK£461k

-UK£40m

Sep 30 2022n/an/a

-UK£36m

Jun 30 2022n/an/a

-UK£39m

Mar 31 2022n/an/a

-UK£39m

Dec 31 2021UK£2mUK£334k

-UK£39m

Vergütung im Vergleich zum Markt: Craig's total compensation ($USD9.43M) is above average for companies of similar size in the US market ($USD3.24M).

Entschädigung vs. Einkommen: Craig's compensation has increased whilst the company is unprofitable.

Geschäftsführer

Craig Tooman (59 yo)

2.8yrs

Amtszeit

UK£7,298,000

Vergütung

Mr. Craig A. Tooman, MBA, serves as President, Chief Executive Officer and Executive Director of Silence Therapeutics plc since February 21, 2022. He has been a Supervisory Director of Curevac N. V. since...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Craig Tooman
President2.8yrsUK£7.30m0.024%
$ 197.3k
Rhonda Hellums
Executive VP2.8yrsUK£2.50m0.0011%
$ 8.9k
Steven Romano
Executive VP and Chief Research & Development Officer1.6yrsUK£1.82m0.0092%
$ 76.5k
Marie Lindholm
Chief Scientific Officerless than a yearkeine Datenkeine Daten
Gem Hopkins
Head of IR & Corporate Communicationsno datakeine Datenkeine Daten
Gianine Esposito
Chief Human Resources Officerless than a yearkeine Datenkeine Daten
Barbara Ruskin
Senior VP and Chief Intellectual Property & Innovation Officer2.2yrskeine Datenkeine Daten
Eric Floyd
Senior Vice President of Regulatory Affairs & Quality Assurance4.3yrskeine Datenkeine Daten
J.P. Gabriel
Chief Technical Operations Officer2yrskeine Datenkeine Daten
Curtis Rambaran
Chief Medical Officerno datakeine Datenkeine Daten

2.1yrs

Durchschnittliche Betriebszugehörigkeit

61yo

Durchschnittliches Alter

Erfahrenes Management: SLN's management team is considered experienced (2.1 years average tenure).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Craig Tooman
President2.8yrsUK£7.30m0.024%
$ 197.3k
David Lemus
Independent Non-Executive Director6.4yrsUK£184.00k0.0054%
$ 44.3k
Gordon Duff
Chairman of Scientific Advisory Board4.8yrskeine Datenkeine Daten
Michael Davidson
Independent Non-Executive Director3.8yrsUK£178.00k0.0092%
$ 76.5k
Iain Ross
Independent Chairman of the Board5.6yrsUK£402.00k0.078%
$ 647.8k
John Porter
Member of Scientific Advisory Board4.8yrskeine Datenkeine Daten
James Ede-Golightly
Independent Non-Executive Director5.6yrsUK£182.00k0.011%
$ 88.4k
Henry Ginsberg
Member of Scientific Advisory Board4.8yrskeine Datenkeine Daten
Annemieke Aartsma-Rus
Member of Scientific Advisory Board4.8yrskeine Datenkeine Daten
John Whittaker
Member of Scientific Advisory Board4.4yrskeine Datenkeine Daten
Jenny Sims
Member of Scientific Advisory Board2.8yrskeine Datenkeine Daten
Tom Brown
Member of Scientific Advisory Board2.8yrskeine Datenkeine Daten

4.8yrs

Durchschnittliche Betriebszugehörigkeit

62yo

Durchschnittliches Alter

Erfahrener Vorstand: SLN's board of directors are considered experienced (4.8 years average tenure).